Highlights of the Eighth European Cancer Conference.
Prescott
L M
LM
D004999:Amifostine / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy; D003131:Combined Modality Therapy; D000077143:Docetaxel; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D000077146:Irinotecan; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D011832:Radiation Injuries / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D043823:Taxoids; D014747:Vinblastine / Q000627:therapeutic use; D000077235:Vinorelbine
D000970:Antineoplastic Agents; D011837:Radiation-Protective Agents; D043823:Taxoids; D000077143:Docetaxel; D014747:Vinblastine; D000077146:Irinotecan; D004999:Amifostine; D017239:Paclitaxel; D000077235:Vinorelbine; D002166:Camptothecin